DiaMedica Therapeutics Stock (NASDAQ:DMAC)
Previous Close
$4.82
52W Range
$2.14 - $5.74
50D Avg
$4.64
200D Avg
$3.58
Market Cap
$208.24M
Avg Vol (3M)
$85.13K
Beta
1.46
Div Yield
-
DMAC Company Profile
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DMAC Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CNTA | Centessa Pharmaceuticals plc |
| IKT | Inhibikase Therapeutics, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| SCPH | scPharmaceuticals Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| MCRB | Seres Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| IOVA | Iovance Biotherapeutics, Inc. |
| ONCY | Oncolytics Biotech Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| MIST | Milestone Pharmaceuticals Inc. |
| LYRA | Lyra Therapeutics, Inc. |